Clinical trial · Observational
Association Between Mitochondrial DNA Content and Risk of Acute Leukemia
Association Between Mitochondrial DNA Content and Risk of Acute Leukemia in Young Adult
NCT03595969CI-TRIAL-00045897completedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Compelling epidemiological evidence indicates that alterations of mitochondrial DNA, including mutations and abnormal content of mitochondrial DNA (mtDNA), are associated with the initiation and development of acute lymphoblastic leukemia (ALL).The aim of this study was to explore association between mtDNA content in peripheral blood cells could be used as a risk predictor for ALL.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Lymphoblastic Leukemia in Children | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Relative copy number of mitochondrial DNA | Diagnostic Test | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- label
- acute leukemia group
- description
- 150 patients were recruited, who have diagnosed with acute leukemia by bone marrow biopsy
- interventionNames
- Diagnostic Test: Relative copy number of mitochondrial DNA
- label
- Control group
- description
- The 50 healthy controls without previous cancer history were recruited from individuals who visited investigator's hospital for physical examination during the same time period as the case enrollment.
- interventionNames
- Diagnostic Test: Relative copy number of mitochondrial DNA
Primary outcomes (1)
- measure
- Relative copy number of mitochondrial DNA
- timeFrame
- From date of admission until the date of discharging from hospital, assessed up to 5 days
- description
Eligibility
Eligibility (as posted)
- Sex
- All
- Maximum age
- 16 Years
Show eligibility criteria text
Inclusion Criteria: * 1.histological confirmed chronic lymphocytic leukemia; 2.preparing for chemotherapy; 3.no preoperative anticancer treatment. Exclusion Criteria: * 1.history of other malignancy; 2.blood transfusion within one month or prior bone marrow transplantation; 3.patients who reluctant to sign informed consent.
References
Publications (0)
Data not yet available
No reference posted for this study.